Neurocrine Biosciences与 Carnie Wilson携手推出面向迟发性运动障碍患者的 ConnectING with Carnie™宣传活动-动脉网

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia

CISION 等信源发布 2025-05-06 20:30



可切换为仅中文







New multimedia awareness campaign empowers people living with tardive dyskinesia to stand up to stigma and speak openly with their healthcare provider about symptoms and treatment

新的多媒体宣传运动赋权迟发性运动障碍患者，抵抗污名并公开与医疗服务提供者讨论症状和治疗。

SAN DIEGO

圣地亚哥

，

May 6, 2025

2025年5月6日

/PRNewswire/ --

Neurocrine Biosciences, Inc.

神经科学生物科学公司

(Nasdaq:

（纳斯达克：

NBIX

) today announced the launch of ConnectING with Carnie™, a multimedia awareness campaign in partnership with Grammy-nominated singer-songwriter and mental health advocate,

）今天宣布推出“与卡尼连接”多媒体宣传活动，该活动与格莱美提名的歌手、词曲作者和心理健康倡导者合作，

Carnie Wilson

卡妮·威尔逊

. The campaign aims to support people struggling with the uncontrolled movements of tardive dyskinesia, an involuntary movement disorder associated with the use of antipsychotic medications, by sharing stories of courage and resilience in seeking diagnosis and treatment.

该活动旨在通过分享勇敢和坚韧寻求诊断和治疗的故事，来支持那些因使用抗精神病药物而患上迟发性运动障碍（一种不自主运动障碍）的人们。

继续阅读

Grammy-nominated singer-songwriter and mental health advocate Carnie Wilson

格莱美提名的歌手、词曲作者和心理健康倡导者卡妮·威尔逊

ConnectING with Carnie raises awareness of tardive dyskinesia (TD) and encourages individuals to stand up to stigma, speak openly about their symptoms without fear or embarrassment and seek diagnosis and treatment. Driven by her personal and family experiences with mental health challenges, Carnie is using her voice to empower those impacted by mental illness and TD to take action.

通过与卡尼的连接，提高了人们对迟发性运动障碍（TD）的认识，并鼓励个人直面病耻感，毫无恐惧或尴尬地公开谈论自己的症状，并寻求诊断和治疗。受到她个人和家人经历心理健康挑战的驱使，卡尼正在利用她的声音，赋能那些受精神疾病和TD影响的人们采取行动。

Through the campaign, she's connecting with individuals and care partners who share their lived experiences with mental illness and TD. This includes discussions about .

通过这项活动，她正在与那些分享他们患有精神疾病和迟发性运动障碍（TD）的生活经历的个人和护理伙伴建立联系。这包括关于的讨论。

INGREZZA

(valbenazine) capsules

缬苯那嗪胶囊

for the treatment of TD in adults.

用于治疗成人TD。

The ultimate aim is to encourage people living with TD to seek the help they deserve.

最终目的是鼓励患有 TD 的人寻求他们应得的帮助。

'Mental health is a topic close to my heart, and I'm grateful for the opportunity to partner with Neurocrine Biosciences to spread hope and positivity by sharing stories, connecting with individuals in the mental health community and encouraging those experiencing uncontrollable movements to speak with their healthcare provider about appropriate treatment,' Carnie said.

卡尼表示：“心理健康是我非常关心的话题，我很感激有机会与Neurocrine Biosciences合作，通过分享故事、与心理健康领域的个人建立联系，并鼓励那些经历无法控制的动作的人与其医疗提供者讨论适当的治疗方案，来传播希望和正能量。”

'I've seen the difference that seeking support and treatment can make, and I want people who may be struggling with tardive dyskinesia to know they do not need to suffer in silence.'.

“我已经看到了寻求支持和治疗所能带来的不同，我希望那些可能正在与迟发性运动障碍抗争的人们知道，他们不必默默忍受痛苦。”

Although Carnie does not have TD, she is committed to advocating for those with the condition. She has been inspired by conversations with mental health advocacy leaders regarding TD and its impact, in addition to individuals living with TD, their care partners and healthcare professionals who have shared experiences and success stories regarding treatment with INGREZZA.

尽管卡尼本人没有TD，但她致力于为患有这种疾病的人倡导。她受到与心理健康倡导领导者关于TD及其影响的对话的启发，同时还受到与患有TD的个人、他们的护理伙伴以及医疗保健专业人员分享的关于使用INGREZZA治疗的经验和成功故事的启发。

Videos featuring interviews of some of these conversations, along with resources for people living with TD, will be available on .

包含对其中一些对话的采访视频以及针对TD患者资源的内容，将在上提供。

ConnectingWithCarnie.com

连接卡尔尼网

。

'We are moved by Carnie's passion to be a guiding voice for people impacted by TD, recognizing that even mild uncontrolled movements can significantly impact everyday activities, personal well-being and interactions with others,' said

“我们被卡尼的热情所感动，她希望成为受TD影响的人们的指导声音，认识到即使是轻微的不受控制的动作也会对日常活动、个人福祉以及与他人的互动产生重大影响，”

Eric Benevich

埃里克·贝内维奇

, Chief Commercial Officer, Neurocrine Biosciences. 'Our goal for ConnectING with Carnie is to reduce stigma, increase understanding and encourage individuals with involuntary movements to consult a healthcare provider for appropriate diagnosis and treatment options, such as INGREZZA.'

Neurocrine Biosciences首席商务官。 “我们与Carnie合作的目的是减少污名，增加理解，并鼓励有不自主运动的个人咨询医疗保健提供者以获得适当的诊断和治疗选择，例如INGREZZA。”

For more information on TD, INGREZZA and this partnership, visit

有关TD、INGREZZA和此合作的更多信息，请访问

ConnectingWithCarnie.com

连接卡尔尼网

。

About ConnectING with Carnie

关于与卡尼的连接ING

™

ConnectING with Carnie™ is a multimedia awareness campaign in partnership with Grammy-nominated singer-songwriter and mental health advocate,

ConnectING with Carnie™ 是一项多媒体宣传活动，与格莱美提名的歌手、词曲作者和心理健康倡导者合作，

Carnie Wilson

卡妮·威尔逊

. The campaign aims to raise awareness of tardive dyskinesia (TD), combat stigma, promote diagnosis and empower patients to self-advocate and explore treatment options, including INGREZZA

该活动旨在提高对迟发性运动障碍（TD）的认识，消除病耻感，促进诊断，并赋予患者自我倡导和探索治疗方案的能力，包括使用INGREZZA。

(valbenazine) capsules, an FDA-approved TD treatment for adults.

（缬苯那嗪）胶囊，一种经FDA批准用于成人的TD治疗药物。

Carnie Wilson

卡妮·威尔逊

is an advocate for those living with mental health conditions and TD.

是精神健康状况和图雷特综合症患者的支持者。

Carnie Wilson

卡妮·威尔逊

is a paid spokesperson for INGREZZA/Neurocrine Biosciences, Inc. She is not diagnosed with TD and does not take INGREZZA. To learn more about the campaign, visit

是INGREZZA/Neurocrine Biosciences公司的付费代言人。她并未被诊断出患有TD，也不服用INGREZZA。欲了解有关该活动的更多信息，请访问

ConnectingWithCarnie.com

连接卡尼网

。

About Tardive Dyskinesia

关于迟发性运动障碍

Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrolled, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with taking certain kinds of mental health medicines (antipsychotics) that help control dopamine receptors in the brain.

迟发性运动障碍（TD）是一种运动障碍，其特征是面部、躯干和/或其他身体部位出现无法控制、异常且重复的运动，这些运动可能会造成干扰并对患者产生负面影响。这种情况与服用某些精神健康药物（抗精神病药）有关，这些药物有助于控制大脑中的多巴胺受体。

Taking antipsychotics commonly prescribed to treat mental illnesses such as major depressive disorder, bipolar disorder, schizophrenia and schizoaffective disorder and other prescription medicines (metoclopramide and prochlorperazine) used to treat gastrointestinal disorders are associated with TD. In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement.

服用常用于治疗重度抑郁症、双相情感障碍、精神分裂症和分裂情感性障碍等精神疾病的抗精神病药物，以及其他用于治疗胃肠疾病的处方药（如甲氧氯普胺和丙氯拉嗪），与迟发性运动障碍（TD）有关。在患有TD的患者中，这些治疗被认为会导致控制运动的大脑区域出现不规则的多巴胺信号传导。

The symptoms of TD can be mild to severe and are often persistent and irreversible. TD is estimated to affect at least 800,000 adults in the U.S..

迟发性运动障碍的症状可能从轻微到严重不等，而且往往持续存在，无法逆转。据估计，美国至少有 80 万成年人受到迟发性运动障碍的影响。

About INGREZZA

关于INGREZZA

(valbenazine) Capsules and INGREZZA

(valbenazine) 胶囊和 INGREZZA

SPRINKLE (valbenazine) Capsules

SPRINKLE（缬苯那嗪）胶囊

INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of adults with tardive dyskinesia and the treatment of chorea associated with Huntington's disease (HD). Only INGREZZA offers a therapeutic dose from day one with no required titration..

INGREZZA 是一种选择性囊泡单胺转运体 2 (VMAT2) 抑制剂，获美国食品药品监督管理局批准用于治疗成人迟发性运动障碍及与亨廷顿病 (HD) 相关的舞蹈症。唯有 INGREZZA 可从第一天起提供治疗剂量，且无需调整剂量。

INGREZZA, developed by Neurocrine Biosciences, selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic or muscarinic receptors. While the specific way INGREZZA works to treat TD and HD chorea is not fully understood, INGREZZA is unique in that it selectively and specifically targets VMAT2 to inhibit the release of dopamine, a chemical in the brain that helps control movement.

INGREZZA由Neurocrine Biosciences开发，可选择性抑制VMAT2，且对VMAT1、多巴胺能（包括D2）、血清素能、肾上腺素能、组胺能或毒蕈碱受体无明显结合亲和力。尽管INGREZZA治疗TD和HD舞蹈症的具体机制尚未完全明确，但其独特之处在于能够选择性且特异性地靶向VMAT2，抑制多巴胺（一种帮助控制大脑运动的化学物质）的释放。

INGREZZA is believed to reduce extra dopamine signaling, which may lead to fewer uncontrollable movements..

INGREZZA被认为可以减少过多的多巴胺信号传导，这可能会导致更少的无法控制的运动。

INGREZZA is proven across the widest range of patients. It is always one capsule, once daily and can be taken together with most stable mental health regimens such as antipsychotics or antidepressants. Only INGREZZA offers the benefit of a sprinkle formulation, INGREZZA SPRINKLE, for those who experience dysphagia, have difficulty swallowing or prefer not to swallow a pill.

INGREZZA 在最广泛的患者群体中得到了验证。它始终是一天一次，一次一粒胶囊，并且可以与大多数稳定的精神健康治疗方案（如抗精神病药或抗抑郁药）一起服用。只有 INGREZZA 提供了撒剂配方，INGREZZA SPRINKLE，适用于有吞咽困难或不想吞服药丸的患者。

INGREZZA and INGREZZA SPRINKLE dosages approved for use are 40 mg, 60 mg and 80 mg capsules. .

INGREZZA和INGREZZA SPRINKLE批准使用的剂量为40毫克、60毫克和80毫克胶囊。

Important Information

重要信息

Approved Uses

批准的用途

INGREZZA

(valbenazine) capsules or INGREZZA

(valbenazine) 胶囊或 INGREZZA

SPRINKLE (valbenazine) capsules are prescription medicines used to treat adults with:

SPRINKLE（缬苯那嗪）胶囊是用于治疗成人以下疾病的处方药：

movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).

面部、舌头或身体其他部位无法控制的动作（迟发性运动障碍）。

involuntary movements (chorea) of Huntington's disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of involuntary movements, and do not treat other symptoms of Huntington's disease, such as problems with thinking or emotions.

亨廷顿病的不自主运动（舞蹈病）。INGREZZA 或 INGREZZA SPRINKLE 不能治愈不自主运动的病因，也不能治疗亨廷顿病的其他症状，例如思维或情绪问题。

It is not known if INGREZZA or INGREZZA SPRINKLE is safe and effective in children.

不知道INGREZZA或INGREZZA SPRINKLE在儿童中是否安全有效。

IMPORTANT SAFETY INFORMATION

重要安全信息

INGREZZA or INGREZZA SPRINKLE can cause serious side effects in people with Huntington's disease, including: depression, suicidal thoughts, or suicidal actions.

INGREZZA 或 INGREZZA SPRINKLE 可能对亨廷顿病患者造成严重的副作用，包括：抑郁、自杀念头或自杀行为。

Tell your healthcare provider before you start taking INGREZZA or INGREZZA SPRINKLE if you have Huntington's disease and are depressed (have untreated depression or depression that is not well controlled by medicine) or have suicidal thoughts. Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.

在开始服用INGREZZA或INGREZZA SPRINKLE之前，请告知您的医疗保健提供者您是否患有亨廷顿病并感到抑郁（有未经治疗的抑郁或药物未能有效控制的抑郁）或有自杀念头。密切注意任何变化，尤其是情绪、行为、思想或感受的突然变化。

This is especially important when INGREZZA or INGREZZA SPRINKLE is started and when the dose is changed. Call your healthcare provider right away if you become depressed, have unusual changes in mood or behavior, or have thoughts of hurting yourself..

这一点在开始使用INGREZZA或INGREZZA SPRINKLE以及剂量改变时尤为重要。如果您感到抑郁、情绪或行为有异常变化，或者有伤害自己的念头，请立即联系您的医疗服务提供者。

Do not take INGREZZA or INGREZZA SPRINKLE if you:

如果您有以下情况，请勿服用 INGREZZA 或 INGREZZA SPRINKLE：

are allergic to valbenazine, or any of the ingredients in INGREZZA or INGREZZA SPRINKLE.

对缬苯那嗪或INGREZZA或INGREZZA SPRINKLE中的任何成分过敏。

INGREZZA or INGREZZA SPRINKLE can cause serious side effects, including:

INGREZZA 或 INGREZZA SPRINKLE 可能导致严重的副作用，包括：

Allergic reactions.

过敏反应。

Allergic reactions, including an allergic reaction that causes sudden swelling called angioedema, can happen after taking the first dose or after many doses of INGREZZA or INGREZZA SPRINKLE. Signs and symptoms of allergic reactions and angioedema include: trouble breathing or shortness of breath, swelling of your face, lips, eyelids, tongue, or throat, or other areas of your skin, trouble with swallowing, or rash, including raised, itchy red areas on your skin (hives).

过敏反应，包括导致突发性肿胀（称为血管性水肿）的过敏反应，可能在服用第一剂或多次剂量的INGREZZA或INGREZZA SPRINKLE后发生。过敏反应和血管性水肿的体征和症状包括：呼吸困难或气短、面部、嘴唇、眼睑、舌头、喉咙或皮肤其他部位的肿胀、吞咽困难、或皮疹，包括皮肤上隆起的、发痒的红色区域（荨麻疹）。

Swelling in the throat can be life-threatening and can lead to death. Stop taking INGREZZA or INGREZZA SPRINKLE and go to the nearest emergency room right away if you develop these signs and symptoms of allergic reactions and angioedema..

喉咙肿胀可能会危及生命，并导致死亡。如果出现过敏反应和血管性水肿的这些症状，请立即停止服用INGREZZA或INGREZZA SPRINKLE，并前往最近的急诊室。

Sleepiness and tiredness that could cause slow reaction times (somnolence and sedation).

可能导致反应时间变慢的困倦和疲惫（嗜睡和镇静）。

Do not drive a car or operate dangerous machinery until you know how INGREZZA or INGREZZA SPRINKLE affects you. Drinking alcohol and taking other medicines may also cause sleepiness during treatment with INGREZZA or INGREZZA SPRINKLE.

在了解INGREZZA或INGREZZA SPRINKLE对您的影响之前，请勿驾驶汽车或操作危险机械。在使用INGREZZA或INGREZZA SPRINKLE治疗期间，饮酒和服用其他药物也可能导致嗜睡。

Heart rhythm problems (QT prolongation).

心律问题（QT间期延长）。

INGREZZA or INGREZZA SPRINKLE may cause a heart rhythm problem known as QT prolongation. You have a higher chance of getting QT prolongation if you also take certain other medicines during treatment with INGREZZA or INGREZZA SPRINKLE. Tell your healthcare provider right away if you develop any signs or symptoms of QT prolongation, including: fast, slow, or irregular heartbeat (heart palpitations), shortness of breath, dizziness or lightheadedness, or fainting or feeling like you are going to faint..

INGREZZA 或 INGREZZA SPRINKLE 可能导致一种称为 QT 间期延长的心律问题。如果您在使用 INGREZZA 或 INGREZZA SPRINKLE 治疗期间同时服用某些其他药物，出现 QT 间期延长的风险会更高。如果您出现任何 QT 间期延长的迹象或症状，请立即告知您的医疗保健提供者，包括：心跳过快、过慢或不规则（心悸）、呼吸急促、头晕或头昏、昏厥或感觉即将昏厥。

Neuroleptic Malignant Syndrome (NMS).

神经阻滞剂恶性综合征 (NMS)。

NMS is a serious condition that can lead to death. Call a healthcare provider right away or go to the nearest emergency room if you develop these symptoms and they do not have another obvious cause: high fever, stiff muscles, problems thinking, irregular pulse or blood pressure, increased sweating, or very fast or uneven heartbeat..

NMS是一种严重的疾病，可能会导致死亡。如果出现以下症状且没有其他明显原因，请立即联系医疗服务提供者或前往最近的急诊室：高烧、肌肉僵硬、思维障碍、脉搏或血压不规律、出汗增多，或心跳非常快或不规则。

Parkinson-like symptoms.

帕金森样症状。

Symptoms include: body stiffness, drooling, trouble moving or walking, trouble keeping your balance, shaking (tremors), or falls.

症状包括：身体僵硬、流口水、移动或行走困难、难以保持平衡、颤抖（震颤）或跌倒。

Before taking INGREZZA or INGREZZA SPRINKLE, tell your healthcare provider about all of your medical conditions including if you:

在服用INGREZZA或INGREZZA SPRINKLE之前，请告诉您的医疗保健提供者您的所有医疗状况，包括您是否：

have liver or heart problems, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.

有肝脏或心脏问题、怀孕或计划怀孕、正在哺乳或计划哺乳。

Tell your healthcare provider about all the medicines you take,

告诉您的医疗保健提供者您所服用的所有药物，

including prescription and over-the-counter medicines, vitamins, and herbal supplements. Make sure you tell all of your healthcare providers that you are taking INGREZZA or INGREZZA SPRINKLE. Taking INGREZZA or INGREZZA SPRINKLE with certain other medicines may cause serious side effects. Especially tell your healthcare provider if you: take digoxin or take or have taken a monoamine oxidase inhibitor (MAOI) medicine.

包括处方药和非处方药、维生素和草药补充剂。确保告诉所有医疗保健提供者您正在服用INGREZZA或INGREZZA SPRINKLE。将INGREZZA或INGREZZA SPRINKLE与某些其他药物一起使用可能会导致严重的副作用。特别是告诉您的医疗保健提供者您是否：服用地高辛或正在服用或曾经服用过单胺氧化酶抑制剂（MAOI）药物。

You should not take INGREZZA or INGREZZA SPRINKLE if you are taking, or have stopped taking, a MAOI within the last 14 days..

如果您在过去14天内正在服用或已停止服用MAOI，则不应服用INGREZZA或INGREZZA SPRINKLE。

The most common side effects of INGREZZA or INGREZZA SPRINKLE in people with tardive dyskinesia

INGREZZA或INGREZZA SPRINKLE在迟发性运动障碍患者中最常见的副作用

are

是

sleepiness and tiredness.

困倦和疲惫。

The most common side effects of INGREZZA or INGREZZA SPRINKLE in people with chorea associated with Huntington's disease include

INGREZZA或INGREZZA SPRINKLE在治疗与亨廷顿病相关的舞蹈症患者中最常见的副作用包括

sleepiness and tiredness, raised itchy red areas on your skin (hives), rash, and trouble getting to sleep or staying asleep.

嗜睡和疲倦，皮肤上出现隆起的发痒红斑（荨麻疹）、皮疹，以及入睡或保持睡眠困难。

These are not all of the possible side effects of INGREZZA or INGREZZA SPRINKLE. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at

这些并非INGREZZA或INGREZZA SPRINKLE的所有可能副作用。如需了解副作用的医疗建议，请咨询您的医生。我们鼓励您向FDA报告处方药的不良副作用。访问MedWatch网站

www.fda.gov/medwatch

or call

或打电话

1-800-FDA-1088.

1-800-FDA-1088。

Dosage Forms and Strengths:

剂型和规格：

INGREZZA and INGREZZA SPRINKLE are available in 40 mg, 60 mg, and 80 mg capsules.

INGREZZA 和 INGREZZA SPRINKLE 有 40 毫克、60 毫克和 80 毫克的胶囊可供选择。

Please see full

请查看完整内容

Prescribing Information

处方信息

, including Boxed Warning, and

，包括加框警告，以及

Medication Guide

药品指南

。

About Neurocrine Biosciences, Inc.

关于Neurocrine Biosciences公司

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders.

Neurocrine Biosciences是一家领先的神经科学-focused生物制药公司，拥有一个简单的使命：减轻高需求患者的痛苦。我们致力于为那些尚未得到充分治疗的神经、神经内分泌和神经精神疾病患者发现和开发生命改变的治疗方法。

The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas.

公司多样化的产品组合包括FDA批准的治疗迟发性运动障碍、亨廷顿病相关的舞蹈症、经典先天性肾上腺增生症、子宫内膜异位症*和子宫肌瘤*的药物，以及一个强大的研发管线，涵盖多个处于中期至晚期临床开发阶段的化合物，横跨我们的核心治疗领域。

For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science. For more information, visit .

三十年来，我们运用自己对神经科学以及大脑和身体系统之间相互联系的独特见解来治疗复杂疾病。我们不懈地研发药物以减轻衰弱性疾病和病症带来的负担，因为您值得拥有勇敢的科学。欲了解更多信息，请访问。

neurocrine.com

, and follow the company on

，关注公司动态请访问

领英

，

and

和

Facebook

. (*

。 (*

in collaboration with AbbVie

与艾伯维合作

)

The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE and INGREZZA are registered trademarks of Neurocrine Biosciences, Inc. ConnectING with Carnie is a trademark of Neurocrine Biosciences, Inc.

NEUROCRINE BIOSCIENCES 徽标、NEUROCRINE、YOU DESERVE BRAVE SCIENCE 和 INGREZZA 是 Neurocrine Biosciences, Inc. 的注册商标。ConnectING with Carnie 是 Neurocrine Biosciences, Inc. 的商标。

Forward-Looking Statements

前瞻性声明

In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from INGREZZA, the value INGREZZA may bring to patients, and the Company's plans to encourage awareness that may help address the needs of people living with tardive dyskinesia (TD).

除历史事实外，本新闻稿还包含涉及若干风险和不确定性的前瞻性陈述。这些陈述包括但不限于有关INGREZZA可能带来的潜在益处、INGREZZA可能为患者带来的价值，以及公司计划推动认知以帮助满足迟发性运动障碍（TD）患者的需要等陈述。

Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: whether the Company can successfully encourage awareness of people living with TD, risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of INGREZZA; whether INGREZZA receives adequate reimbursement from third-party payors; risks and uncertainties relating to competitive products and technological changes that may limit demand for INGREZZA; risks associated with the Company's dependence on third parties for development and manufacturing activities related to INGREZZA, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for INGREZZA or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding INGREZZA; risks that post-approval INGREZZA commitments or requirements may be delayed; risks that INGREZZA may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and other risks described in the Company's.

可能导致实际结果与前瞻性陈述中所述或暗示的结果存在重大差异的因素包括但不限于以下：公司是否能够成功提高人们对迟发性运动障碍（TD）患者的认知，与Neurocrine Biosciences业务和财务相关的风险和不确定性，以及与INGREZZA商业化相关的风险和不确定性；INGREZZA是否能从第三方支付方获得足够的报销；与竞争产品及可能限制对INGREZZA需求的技术变革相关的风险和不确定性；公司依赖第三方进行与INGREZZA相关的开发和制造活动的风险，以及公司管理这些第三方的能力相关的风险；关于INGREZZA或其他候选产品的额外监管提交可能不会发生或未能及时提交的风险；FDA或其他监管机构可能对INGREZZA做出不利决定的风险；INGREZZA的批准后承诺或要求可能被延迟的风险；INGREZZA可能因第三方的专利或监管权利而被排除在商业化之外，或者可能出现意外的副作用、不良反应或误用事件；以及公司在文件中描述的其他风险。

March 31, 2025

2025年3月31日

. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law.

Neurocrine Biosciences否认有任何义务在本新闻稿发布日期之后更新其中包含的声明，除非法律要求。

REFERENCE

参考文献

1. INGREZZA capsules [package insert].

1. INGREZZA胶囊[包装说明书]。

San Diego, CA

加利福尼亚州圣地亚哥

: Neurocrine Biosciences; 2024.

神经内分泌生物科学；2024。

SOURCE Neurocrine Biosciences, Inc.

来源：Neurocrine Biosciences, Inc.

WANT YOUR COMPANY'S NEWS